NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
Anahita DasturAHyun ChoiCarlotta CostaXunqin YinAugust WilliamsJoseph McClanaghanMax GreenbergJustine RoderickNeha U PatelJessica BoisvertUltan McDermottMathew J GarnettJorge AlmenaraSteven GrantKathryn RizzoJeffrey A EngelmanMichelle KelliherAnthony C FaberCyril H BenesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Our results support the development of navitoclax, as single agent and in combination with mTOR inhibitors, as a new therapeutic strategy for T-ALL, including in the setting of GSI resistance.
Keyphrases